INZY News and Press, Inozyme Pharma Inc. From 04/12/22

- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – - Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABCC6 Deficiency expected in the second quarter of 2022 – - Second cohort in Phase 1/2 clinical trial in ENPP1 D...

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief ...

Inozyme Pharma (INZY +15.1%), a biotech focused on rare diseases, is trading sharply higher in the morning hours Monday after announcing Phase 1/2 data for its lead candidate, INZ-701 in ENPP1 Deficiency, a condition with no approved therapies. The open-label trial is currently underway in No...

Protalix BioTherapeutics (PLX) +48% as PRX–102 for Fabry disease equals Sanofi's Fabrazyme in trial. SPI Energy (SPI) +28%. Twitter (TWTR) +20% Trump SPAC Digital World sinks on report two Truth Social executives left, Musk takes Twitter stake. Red Cat Holdings (OTC...

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three patients in lowest dose cohort (0.2 mg/kg) – - PPi increased in all three patients to levels comparable to those observed in a study of healthy subjects - - INZ...

Inozyme Pharma press release (NASDAQ:INZY): FY GAAP EPS of -$2.40 misses by $0.11. Cash, cash equivalents, and investments were $111.8 million as of December 31, 2021. For further details see: Inozyme Pharma GAAP EPS of -$2.40 misses by $0.11

– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway – – Expect to enroll first patient in Phase 1/2 trial of INZ-701 for ABCC6 Deficiency in the second quarter of 2022 – – Preliminary safety an...

Inozyme Pharma (NASDAQ:INZY) has announced two executive appointments, with Sanjay Subramanian joining the team as CFO and Soojin Kim as SVP and Chief Technical Operations Officer (CTOO). Mr. Subramanian has over 20 years of corporate finance, capital markets, and business development experti...

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Sanjay S. Subramanian, M.S., MBA, as chi...

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief ...